Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
T-B+ severe combined immunodeficiency due to CD45 deficiency
T-B+ severe combined immunodeficiency due to CD45 deficiency
T-B+ severe combined immunodeficiency due to CD45 deficiency
Synonyms: T-B+ SCID due to CD45 deficiency
Synonyms: T-B+ SCID due to CD45 deficiency
Synonyms: T-B+ SCID due to CD45 deficiency
Drug discovery
31
papers
On emerging therapies
Rare immune diseases
T-B+ severe combined immunodeficiency due to CD45 deficiency
Overview
T-B+ Severe Combined Immunodeficiency Due to CD45 Deficiency is a rare autosomal recessive disorder characterized by markedly reduced T-cell counts, normal/increased B and NK cells, and hypogammaglobulinemia. It results from PTPRC gene mutations disrupting CD45 tyrosine phosphatase, critical for T-cell receptor signaling and thymic development. Infants present with severe infections (viral, bacterial, fungal), failure to thrive, hepatosplenomegaly, and pancytopenia. Diagnosis relies on absent CD45 expression via flow cytometry, genetic testing, and impaired T-cell proliferation [1][6][11].
Therapies
Hematopoietic stem cell transplantation (HSCT): Curative; success rates >90% with early HLA-matched donor transplants [11][16].
Supportive care: Prophylactic antimicrobials (e.g., trimethoprim-sulfamethoxazole), IVIG replacement, and strict infection control [6][14].
Avoid live vaccines/CMV+ blood products: Prevents life-threatening complications [6][14].
Categories: rare genetic diseases, rare immunological diseases, rare transplant-related disorders
Research Papers
31 drug discovery papers about T-B+ severe combined immunodeficiency due to CD45 deficiency. Recent publications:
31 drug discovery papers about T-B+ severe combined immunodeficiency due to CD45 deficiency. Recent publications:
categories:
Small molecules
cell therapies
2022-08-29 | Depletion of CD45RA+ naïve T cells for haploidentical stem cell transplantations: graft generation under good manufacturing practice and establishment of a flow cytometric quality control for clinical-scale grafts
In haploidentical stem cell transplantation (SCT), achieving a balance between graft versus host disease (GvHD), graft versus leukemia effect (GvL) and bridging the vulnerable phase of aplasia against viral infections is still a challenge. Graft preparation strategies attempt to achieve this balance by removing and retaining harmful and helpful cells. At this point it is known that T cell subpopulations hold different properties concerning GvHD promotion and immunocompetence towards pathogens. CD45RA+ naïve T cells show the greatest, while CD45RO+ memory T cells show less alloreactive potential but provide immunocompetence. CD45RA depletion is a promising new approach to graft processing that potentially combines GvHD prevention, GvL promotion and transfer of immunological competence by removing potentially harmful CD45RA+ naïve T cells and retaining CD45RO+ memory cells. This work focused on manufacturing CD45RA-depleted grafts within a one- or two-step approach, as well as a feasibility assessment of the process and the establishment of a 10-color fluorescence activated cell sorting (FACS) measurement panel for clinical-scale graft generation. CD45RA depletions were conducted from granulocyte-colony stimulated factor (G-CSF) mobilized peripheral blood stem cells (PBSC) applying two different strategies, direct depletion of CD45RA+ cells (one-step approach), or depletion following preceding CD34 selection. A 10-color FACS measurement panel was established ensuring quality control and enabling preliminary data acquisition on CD45RA co-expression for cell loss estimations. Residual virus-specific T cells after depletion were measured using MHC multimers. It was observed that the depletion antibody occupied the cell binding sites, resulting in insufficient binding of the fluorescent dye for subsequent FACS measurement. Therefore, three FACS antibodies were tested and compared, and CD45RA-PE (clone:2H4) was found to be the best choice for reliable cell detection. To further characterize residual T cells, two homing markers, CD62L and CCR7, were compared, with particular attention paid to the expression of the surface markers after cooling. Both markers were complementary to each other, resulting in the decision to include an additional FACS measuring tube whenever samples are cooled or further T cell characterization is needed. With a median log depletion of -3.9 (one-step) and -3.8 (two-step) data showed equally efficient removal of CD45RA+CD3+ T cells for both approaches. Close to complete B cell removal was obtained without additional reagent use. However, also close to complete NK cell loss occurred due to high CD45RA co-expression. Stem cells recovered at a median of 52% (range: 49.7 - 67.2%) after one-step CD45RA depletion. CD45RO+ memory T cells recovery was statistically not differing between both approaches. Virus-specific T cells were detectable after depletion, suggesting that virus-specific immunocompetence is transferable. In conclusion, CD45RA depletions are equally feasible for both approaches when performed from fresh, non-cryopreserved starting products, show reliable reduction of CD45RA and B cells, but also result in co-depletion of NK cells. Stem cell recovery and NK cell losses must be considered carefully especially regarding overcoming HLA barriers, pathogen protection during aplasia, early engraftment an GvL. Therefore, a combination of CD45RA-depleted products with already established other processing methods to ensure sufficient stem and NK cells is desirable to allow high clinical flexibility.
2022-06-09 | First CD3/CD45RA depleted haploidentical transplant for severe combined immunodeficiency disease with Rotavirus gastroenteritis in Vietnam
Severe combined immunodeficiency includes inherited diseases with impairment of T cells development, often associated with profound defects of B and/or NK cells differentiation. Rotavirus infection is responsible for severe acute gastroenteritis and over 400,000 deaths a year in children aged < 5 years, especially in low and middle-income countries. We report a nine-month-old girl presented with failure to thrive left axillary lymphadenitis post-BCG-vaccination, persistent, nonvaccine-associated rotavirus gastroenteritis. An immune evaluation revealed absent T lymphocytes, B lymphocytes, normal NK cells with genetic testing confirmed RAG2 severe combined immunodeficiency. Rotavirus gastroenteritis persisted despite the administration of oral immunoglobulin pre-transplantation. The patient was treated by a haploidentical transplant -from mother as a donor using CD3/CD45RA+ depletion kit, CliniMACs system (Miltenyi). The first transplant was performed without conditioning. One month post-transplant, rotavirus was cleared. The second transplant was performed three months later, with myeloablative conditioning (Bu-Flu-rATG). Neutrophils engrafted on day +10 post-transplant, platelet engrafted on day +45. Whole blood chimerism on day +28 post 2nd transplant was 100%. Serum IgG level has been normalized without IVIG infusion three months post 2nd transplant.
2020-01-17 | Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor
Abstract Attempts to expand ex vivo the numbers of human hematopoietic stem cells (HSCs) without compromising their marrow repopulating capacity and their ability to establish multilineage hematopoiesis has been the subject of intense investigation. Although most such efforts have focused on cord blood HSCs, few have been applied to adult HSCs, a more clinically relevant HSC source for gene modification. To date, the strategies that have been used to expand adult HSCs have resulted in modest effects or HSCs with lineage bias and a limited ability to generate T cells in vivo. We previously reported that culturing umbilical cord blood CD34+ cells in serum-free media supplemented with valproic acid (VPA), a histone deacetylase inhibitor, and a combination of cytokines led to the expansion of the numbers of fully functional HSCs. In the present study, we used this same approach to expand the numbers of adult human CD34+ cells isolated from mobilized peripheral blood and bone marrow. This approach resulted in a significant increase in the numbers of phenotypically defined HSCs (CD34+CD45RA-CD90+D49f+). Cells incubated with VPA also exhibited increased aldehyde dehydrogenase activity and decreased mitochondrial membrane potential, each functional markers of HSCs. Grafts harvested from VPA-treated cultures were able to engraft in immune-deficient mice and, importantly, to generate cellular progeny belonging to each hematopoietic lineage in similar proportion to that observed with unmanipulated CD34+ cells. These data support the utility of VPA-mediated ex vivo HSC expansion for gene modification of adult HSCs. Significance statement This study shows that the transplantation of ex vivo valproic acid (VPA)-treated, adult mobilized peripheral blood and bone marrow hematopoietic stem cells (HSCs) into immune-deficient mice led to nonbiased long-term multilineage hematopoietic cell engraftment including T cells. These data support the use of VPA-mediated ex vivo HSC expansion for future gene modification strategies.
2016-11-21 | Reprogramming mouse fibroblasts into engraftable myeloerythroid and lymphoid progenitors
Recent efforts have attempted to convert non-blood cells into hematopoietic stem cells (HSCs) with the goal of generating blood lineages de novo. Here we show that hematopoietic transcription factors Scl, Lmo2, Runx1 and Bmi1 can convert a developmentally distant lineage (fibroblasts) into 'induced hematopoietic progenitors' (iHPs). Functionally, iHPs generate acetylcholinesterase+ megakaryocytes and phagocytic myeloid cells in vitro and can also engraft immunodeficient mice, generating myeloerythoid and B-lymphoid cells for up to 4 months in vivo. Molecularly, iHPs transcriptionally resemble native Kit+ hematopoietic progenitors. Mechanistically, reprogramming factor Lmo2 implements a hematopoietic programme in fibroblasts by rapidly binding to and upregulating the Hhex and Gfi1 genes within days. Moreover the reprogramming transcription factors also require extracellular BMP and MEK signalling to cooperatively effectuate reprogramming. Thus, the transcription factors that orchestrate embryonic hematopoiesis can artificially reconstitute this programme in developmentally distant fibroblasts, converting them into engraftable blood progenitors.
2014-06-02 | Rag Defects and Thymic Stroma: Lessons from Animal Models
Thymocytes and thymic epithelial cells (TECs) cross-talk is essential to support T-cell development and preserve thymic architecture and maturation of TECs and Foxp3+ natural regulatory T (nTreg) cells. Accordingly, disruption of thymic lymphostromal cross-talk may have major implications on the thymic mechanisms that govern T cell tolerance. Several genetic defects have been described in humans that affect early stages of T cell development (leading to Severe Combined Immune Deficiency, SCID) or late stages in thymocyte maturation (resulting in combined immunodeficiency). Hypomorphic mutations in SCID-causing genes may allow for generation of a limited pool of T lymphocytes with a restricted repertoire. These conditions are often associated with infiltration of peripheral tissues by activated T cells and immune dysregulation, as best exemplified by Omenn syndrome (OS). In this review, we will discuss our recent findings on abnormalities of thymic microenvironment in OS with a special focus of defective maturation of TECs, altered distribution of thymic dendritic cells (DCs) and impairment of deletional and non-deletional mechanisms of central tolerance. Here, taking advantage of mouse models of OS and atypical SCID, we will discuss how modifications in stromal compartment impact and shape lymphocyte differentiation, and vice versa how inefficient T cell signalling results in defective stromal maturation. These findings are instrumental to understand the extent to which novel therapeutic strategies should act on thymic stroma to achieve full immune reconstitution.
gene therapies
2023-06-28 | Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of mice
Human CD34 + hematopoietic stem and progenitor cells (HSPCs) are a standard source of cells for clinical HSC transplantations as well as experimental xenotransplantation to generate “humanized mice”. To further extend the range of applications of these humanized mice, we developed a protocol to efficiently edit the genomes of human CD34 + HSPCs before transplantation. In the past, manipulating HSPCs has been complicated by the fact that they are inherently difficult to transduce with lentivectors, and rapidly lose their stemness and engraftment potential during in vitro culture. However, with optimized nucleofection of sgRNA:Cas9 ribonucleoprotein complexes, we are now able to edit a candidate gene in CD34 + HSPCs with almost 100% efficiency, and transplant these modified cells in immunodeficient mice with high engraftment levels and multilineage hematopoietic differentiation. The result is a humanized mouse from which we knocked out a gene of interest from their human immune system.
oligonucleotides
2023-10-17 | Temporal regulation of transgene expression controlled by amino acid availability in human T cells
T cell therapy strategies, from allogeneic stem cell transplantation toward genetically‐modified T cells infusion, develop powerful anti‐tumor effects but are often accompanied by side effects and their efficacy remains sometimes to be improved. It therefore appears important to provide a flexible and easily reversible gene expression regulation system to control T cells activity. We developed a gene expression regulation technology that exploits the physiological GCN2‐ATF4 pathway's ability to induce gene expression in T cells in response to one essential amino acid deficiency. We first demonstrated the functionality of NUTRIREG in human T cells by transient expression of reporter genes. We then validated that NUTRIREG can be used in human T cells to transiently express a therapeutic gene such as IL‐10. Overall, our results represent a solid basis for the promising use of NUTRIREG to regulate transgene expression in human T cells in a reversible way, and more generally for numerous preventive or curative therapeutic possibilities in cellular immunotherapy strategies.
cell therapies
2022-08-29 | Depletion of CD45RA+ naïve T cells for haploidentical stem cell transplantations: graft generation under good manufacturing practice and establishment of a flow cytometric quality control for clinical-scale grafts
In haploidentical stem cell transplantation (SCT), achieving a balance between graft versus host disease (GvHD), graft versus leukemia effect (GvL) and bridging the vulnerable phase of aplasia against viral infections is still a challenge. Graft preparation strategies attempt to achieve this balance by removing and retaining harmful and helpful cells. At this point it is known that T cell subpopulations hold different properties concerning GvHD promotion and immunocompetence towards pathogens. CD45RA+ naïve T cells show the greatest, while CD45RO+ memory T cells show less alloreactive potential but provide immunocompetence. CD45RA depletion is a promising new approach to graft processing that potentially combines GvHD prevention, GvL promotion and transfer of immunological competence by removing potentially harmful CD45RA+ naïve T cells and retaining CD45RO+ memory cells. This work focused on manufacturing CD45RA-depleted grafts within a one- or two-step approach, as well as a feasibility assessment of the process and the establishment of a 10-color fluorescence activated cell sorting (FACS) measurement panel for clinical-scale graft generation. CD45RA depletions were conducted from granulocyte-colony stimulated factor (G-CSF) mobilized peripheral blood stem cells (PBSC) applying two different strategies, direct depletion of CD45RA+ cells (one-step approach), or depletion following preceding CD34 selection. A 10-color FACS measurement panel was established ensuring quality control and enabling preliminary data acquisition on CD45RA co-expression for cell loss estimations. Residual virus-specific T cells after depletion were measured using MHC multimers. It was observed that the depletion antibody occupied the cell binding sites, resulting in insufficient binding of the fluorescent dye for subsequent FACS measurement. Therefore, three FACS antibodies were tested and compared, and CD45RA-PE (clone:2H4) was found to be the best choice for reliable cell detection. To further characterize residual T cells, two homing markers, CD62L and CCR7, were compared, with particular attention paid to the expression of the surface markers after cooling. Both markers were complementary to each other, resulting in the decision to include an additional FACS measuring tube whenever samples are cooled or further T cell characterization is needed. With a median log depletion of -3.9 (one-step) and -3.8 (two-step) data showed equally efficient removal of CD45RA+CD3+ T cells for both approaches. Close to complete B cell removal was obtained without additional reagent use. However, also close to complete NK cell loss occurred due to high CD45RA co-expression. Stem cells recovered at a median of 52% (range: 49.7 - 67.2%) after one-step CD45RA depletion. CD45RO+ memory T cells recovery was statistically not differing between both approaches. Virus-specific T cells were detectable after depletion, suggesting that virus-specific immunocompetence is transferable. In conclusion, CD45RA depletions are equally feasible for both approaches when performed from fresh, non-cryopreserved starting products, show reliable reduction of CD45RA and B cells, but also result in co-depletion of NK cells. Stem cell recovery and NK cell losses must be considered carefully especially regarding overcoming HLA barriers, pathogen protection during aplasia, early engraftment an GvL. Therefore, a combination of CD45RA-depleted products with already established other processing methods to ensure sufficient stem and NK cells is desirable to allow high clinical flexibility.
2022-06-09 | First CD3/CD45RA depleted haploidentical transplant for severe combined immunodeficiency disease with Rotavirus gastroenteritis in Vietnam
Severe combined immunodeficiency includes inherited diseases with impairment of T cells development, often associated with profound defects of B and/or NK cells differentiation. Rotavirus infection is responsible for severe acute gastroenteritis and over 400,000 deaths a year in children aged < 5 years, especially in low and middle-income countries. We report a nine-month-old girl presented with failure to thrive left axillary lymphadenitis post-BCG-vaccination, persistent, nonvaccine-associated rotavirus gastroenteritis. An immune evaluation revealed absent T lymphocytes, B lymphocytes, normal NK cells with genetic testing confirmed RAG2 severe combined immunodeficiency. Rotavirus gastroenteritis persisted despite the administration of oral immunoglobulin pre-transplantation. The patient was treated by a haploidentical transplant -from mother as a donor using CD3/CD45RA+ depletion kit, CliniMACs system (Miltenyi). The first transplant was performed without conditioning. One month post-transplant, rotavirus was cleared. The second transplant was performed three months later, with myeloablative conditioning (Bu-Flu-rATG). Neutrophils engrafted on day +10 post-transplant, platelet engrafted on day +45. Whole blood chimerism on day +28 post 2nd transplant was 100%. Serum IgG level has been normalized without IVIG infusion three months post 2nd transplant.
2020-01-17 | Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor
Abstract Attempts to expand ex vivo the numbers of human hematopoietic stem cells (HSCs) without compromising their marrow repopulating capacity and their ability to establish multilineage hematopoiesis has been the subject of intense investigation. Although most such efforts have focused on cord blood HSCs, few have been applied to adult HSCs, a more clinically relevant HSC source for gene modification. To date, the strategies that have been used to expand adult HSCs have resulted in modest effects or HSCs with lineage bias and a limited ability to generate T cells in vivo. We previously reported that culturing umbilical cord blood CD34+ cells in serum-free media supplemented with valproic acid (VPA), a histone deacetylase inhibitor, and a combination of cytokines led to the expansion of the numbers of fully functional HSCs. In the present study, we used this same approach to expand the numbers of adult human CD34+ cells isolated from mobilized peripheral blood and bone marrow. This approach resulted in a significant increase in the numbers of phenotypically defined HSCs (CD34+CD45RA-CD90+D49f+). Cells incubated with VPA also exhibited increased aldehyde dehydrogenase activity and decreased mitochondrial membrane potential, each functional markers of HSCs. Grafts harvested from VPA-treated cultures were able to engraft in immune-deficient mice and, importantly, to generate cellular progeny belonging to each hematopoietic lineage in similar proportion to that observed with unmanipulated CD34+ cells. These data support the utility of VPA-mediated ex vivo HSC expansion for gene modification of adult HSCs. Significance statement This study shows that the transplantation of ex vivo valproic acid (VPA)-treated, adult mobilized peripheral blood and bone marrow hematopoietic stem cells (HSCs) into immune-deficient mice led to nonbiased long-term multilineage hematopoietic cell engraftment including T cells. These data support the use of VPA-mediated ex vivo HSC expansion for future gene modification strategies.
2016-11-21 | Reprogramming mouse fibroblasts into engraftable myeloerythroid and lymphoid progenitors
Recent efforts have attempted to convert non-blood cells into hematopoietic stem cells (HSCs) with the goal of generating blood lineages de novo. Here we show that hematopoietic transcription factors Scl, Lmo2, Runx1 and Bmi1 can convert a developmentally distant lineage (fibroblasts) into 'induced hematopoietic progenitors' (iHPs). Functionally, iHPs generate acetylcholinesterase+ megakaryocytes and phagocytic myeloid cells in vitro and can also engraft immunodeficient mice, generating myeloerythoid and B-lymphoid cells for up to 4 months in vivo. Molecularly, iHPs transcriptionally resemble native Kit+ hematopoietic progenitors. Mechanistically, reprogramming factor Lmo2 implements a hematopoietic programme in fibroblasts by rapidly binding to and upregulating the Hhex and Gfi1 genes within days. Moreover the reprogramming transcription factors also require extracellular BMP and MEK signalling to cooperatively effectuate reprogramming. Thus, the transcription factors that orchestrate embryonic hematopoiesis can artificially reconstitute this programme in developmentally distant fibroblasts, converting them into engraftable blood progenitors.
2014-06-02 | Rag Defects and Thymic Stroma: Lessons from Animal Models
Thymocytes and thymic epithelial cells (TECs) cross-talk is essential to support T-cell development and preserve thymic architecture and maturation of TECs and Foxp3+ natural regulatory T (nTreg) cells. Accordingly, disruption of thymic lymphostromal cross-talk may have major implications on the thymic mechanisms that govern T cell tolerance. Several genetic defects have been described in humans that affect early stages of T cell development (leading to Severe Combined Immune Deficiency, SCID) or late stages in thymocyte maturation (resulting in combined immunodeficiency). Hypomorphic mutations in SCID-causing genes may allow for generation of a limited pool of T lymphocytes with a restricted repertoire. These conditions are often associated with infiltration of peripheral tissues by activated T cells and immune dysregulation, as best exemplified by Omenn syndrome (OS). In this review, we will discuss our recent findings on abnormalities of thymic microenvironment in OS with a special focus of defective maturation of TECs, altered distribution of thymic dendritic cells (DCs) and impairment of deletional and non-deletional mechanisms of central tolerance. Here, taking advantage of mouse models of OS and atypical SCID, we will discuss how modifications in stromal compartment impact and shape lymphocyte differentiation, and vice versa how inefficient T cell signalling results in defective stromal maturation. These findings are instrumental to understand the extent to which novel therapeutic strategies should act on thymic stroma to achieve full immune reconstitution.
gene therapies
2023-06-28 | Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of mice
Human CD34 + hematopoietic stem and progenitor cells (HSPCs) are a standard source of cells for clinical HSC transplantations as well as experimental xenotransplantation to generate “humanized mice”. To further extend the range of applications of these humanized mice, we developed a protocol to efficiently edit the genomes of human CD34 + HSPCs before transplantation. In the past, manipulating HSPCs has been complicated by the fact that they are inherently difficult to transduce with lentivectors, and rapidly lose their stemness and engraftment potential during in vitro culture. However, with optimized nucleofection of sgRNA:Cas9 ribonucleoprotein complexes, we are now able to edit a candidate gene in CD34 + HSPCs with almost 100% efficiency, and transplant these modified cells in immunodeficient mice with high engraftment levels and multilineage hematopoietic differentiation. The result is a humanized mouse from which we knocked out a gene of interest from their human immune system.
oligonucleotides
2023-10-17 | Temporal regulation of transgene expression controlled by amino acid availability in human T cells
T cell therapy strategies, from allogeneic stem cell transplantation toward genetically‐modified T cells infusion, develop powerful anti‐tumor effects but are often accompanied by side effects and their efficacy remains sometimes to be improved. It therefore appears important to provide a flexible and easily reversible gene expression regulation system to control T cells activity. We developed a gene expression regulation technology that exploits the physiological GCN2‐ATF4 pathway's ability to induce gene expression in T cells in response to one essential amino acid deficiency. We first demonstrated the functionality of NUTRIREG in human T cells by transient expression of reporter genes. We then validated that NUTRIREG can be used in human T cells to transiently express a therapeutic gene such as IL‐10. Overall, our results represent a solid basis for the promising use of NUTRIREG to regulate transgene expression in human T cells in a reversible way, and more generally for numerous preventive or curative therapeutic possibilities in cellular immunotherapy strategies.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.